Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
09.07. | Update: MSD confirms $10bn takeover deal for Verona Pharma | ||
09.07. | Novo Nordisk files high-dose Wegovy in EU | ||
09.07. | Is MSD preparing a $10bn deal to buy Verona Pharma? | ||
09.07. | New radiopharma Actithera emerges with $75.5m in financing | ||
08.07. | Taiho's late-stage Duchenne candidate fails trial | ||
08.07. | Boehringer raises hope of oral drug for diabetic eye disease | ||
08.07. | First malaria drug for newborns and young infants cleared | ||
08.07. | Medical groups sue RFK Jr over COVID-19 policies | ||
08.07. | Samsung builds digital health credentials with Xealth buy | ||
07.07. | Apogee rises as long-acting eczema drug heads for phase 3 | ||
07.07. | KalVista bags FDA approval for delayed oral HAE drug | ||
07.07. | Charities call for shake-up in UK rare disease R&D | ||
07.07. | Trump signs Medicaid-slashing budget into law | ||
07.07. | J&J bids to extend prostate cancer uses for Akeega | ||
04.07. | UK pharma has concerns about the new NHS 10-year plan | ||
04.07. | AZ claims EU okay for Imfinzi in bladder cancer | ||
04.07. | Pharma welcomes EU push to restore life sciences sector | ||
03.07. | Summit Therapeutics climbs on rumour of $15bn AstraZeneca interest | ||
03.07. | NICE relents on Takeda colorectal cancer drug Fruzaqla | ||
03.07. | The NHS 10-year plan arrives - what are the highlights? | ||
03.07. | Dizal set to bring lung cancer drug Zegfrovy to US | ||
03.07. | Novartis drug flunks phase 3 test in giant cell arteritis | ||
03.07. | Regeneron gets long-awaited FDA okay for myeloma drug | ||
03.07. | UK government reveals neighbourhood healthcare delivery plan | ||
02.07. | GlucoModicum's non-invasive CGM nears first filing |